Genetically Elevated C-Reactive Protein and Ischemic Vascular Disease
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Elevated levels of C-reactive protein (CRP) are associated with increased risks of ischemic heart disease and ischemic cerebrovascular disease. We tested whether this is a causal association. METHODS: We studied 10,276 persons from a general population cohort, including 1786 in whom ischemic heart disease developed and 741 in whom ischemic cerebrovascular disease developed. We examined another 31,992 persons from a cross-sectional general population study, of whom 2521 had ischemic heart disease and 1483 had ischemic cerebrovascular disease. Finally, we compared 2238 patients with ischemic heart disease with 4474 control subjects and 612 patients with ischemic cerebrovascular disease with 1224 control subjects. We measured levels of high-sensitivity CRP and conducted genotyping for four CRP polymorphisms and two apolipoprotein E polymorphisms. RESULTS: The risk of ischemic heart disease and ischemic cerebrovascular disease was increased by a factor of 1.6 and 1.3, respectively, in persons who had CRP levels above 3 mg per liter, as compared with persons who had CRP levels below 1 mg per liter. Genotype combinations of the four CRP polymorphisms were associated with an increase in CRP levels of up to 64%, resulting in a theoretically predicted increased risk of up to 32% for ischemic heart disease and up to 25% for ischemic cerebrovascular disease. However, these genotype combinations were not associated with an increased risk of ischemic vascular disease. In contrast, apolipoprotein E genotypes were associated with both elevated cholesterol levels and an increased risk of ischemic heart disease. CONCLUSIONS: Polymorphisms in the CRP gene are associated with marked increases in CRP levels and thus with a theoretically predicted increase in the risk of ischemic vascular disease. However, these polymorphisms are not in themselves associated with an increased risk of ischemic vascular disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Additional biomarkers, including apo B, lipoprotein(a), high-sensitivity C-reactive protein (CRP), coronary artery calcification score, and ankle-brachial index, are independent risk factors associated with increased risk of ASCVD events and may be helpful when the lipid management goal is unclear.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [284]
In the citing paper
“The value of hsCRP as a CV risk factor appears similar to that of conventional CV risk factors – hsCRP is not a causal factor for CV disease and serves as a biomarker only [36].”
From Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials (2022) · cites this paper as [36]
In the citing paper
“PAD is a common manifestation of atherosclerosis and such patients are at elevated risk of coronary events, with PAD representing an independent risk factor for MI and CV death [510,511].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [511]
In the citing paper
“PAD is a common manifestation of atherosclerosis and such patients are at elevated risk of coronary events, with PAD representing an independent risk factor for MI and CV death [510,511].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [511]
In the citing paper
“Yet, despite the high CV morbidity and mortality risk, PAD patients are usually inadequately managed compared with CAD patients [511].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [511]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Davey Smith, G., & Ebrahim, S. (2003) · International Journal of Epidemiology · doi:10.1093/ije/dyg070 · Cited by 5,882
Danesh, J., Wheeler, J. G., Hirschfield, G. M., Eda, S., Eiriksdottir, G., Rumley, A., Lowe, G. D. O., Pepys, M. B., & Gudnason, V. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032804 · Cited by 2,953
Clinical application of C-reactive protein for cardiovascular disease detection and prevention
Ridker, P. M. (2003) · Circulation · doi:10.1161/01.cir.0000053730.47739.3c · Cited by 2,513
Nordestgaard, B. G., Benn, M., Schnohr, P., & Tybjærg-Hansen, A. (2007) · JAMA · doi:10.1001/jama.298.3.299 · Cited by 2,058
Self-citationFasting compared with nonfasting triglycerides and risk of cardiovascular events in women
Bansal, S., Buring, J. E., Rifai, N., Mora, S., Sacks, F. M., & Ridker, P. M. (2007) · JAMA · doi:10.1001/jama.298.3.309 · Cited by 1,619
Newly identified loci that influence lipid concentrations and risk of coronary artery disease
Willer, C. J., Sanna, S., Jackson, A. U., Scuteri, A., Bonnycastle, L. L., Clarke, R., Heath, S. C., Timpson, N. J., Najjar, S. S., Stringham, H. M., et al. (2008) · Nature Genetics · doi:10.1038/ng.76 · Cited by 1,585
Kathiresan, S., Melander, O., Guiducci, C., Surti, A., Burtt, N. P., Rieder, M. J., Cooper, G. M., Roos, C., Voight, B. F., Havulinna, A. S., et al. (2008) · Nature Genetics · doi:10.1038/ng.75 · Cited by 1,386
Mendelian randomization: prospects, potentials, and limitations
Smith, G. D. (2004) · International Journal of Epidemiology · doi:10.1093/ije/dyh132 · Cited by 1,222
Clarke, R., Shipley, M., Lewington, S., Youngman, L., Collins, R., Marmot, M., & Peto, R. (1999) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a010013 · Cited by 877
Cited by
Items 601–700 of 840
Huang, Y., Chen, C., Wang, T.-Y., NGUYEN, H. T. T., Chen, Y., Wu, C.-M., Chang, Y., Liao, W., & Tsai, F. (2019) · In Vivo · doi:10.21873/invivo.11656 · Cited by 7
C-reactive protein and chronic hepatitis C virus infection in diabetic patients
Skowroński, M., Zozulińska‐Ziółkiewicz, D., Juszczyk, J., Michalski, W., & Wierusz‐Wysocka, B. (2010) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.1001 · Cited by 7
Wang, Q., Sui, Y., Zhang, L.-T., Meng, N., & Chen, H. (2025) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2025.08.013 · Cited by 9
Casula, M., Tragni, E., Zambon, A., Filippi, A., Brignoli, O., Cricelli, C. A., Poli, A., & Catapano, A. L. (2012) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2012.09.010 · Cited by 7
“with higher rates of ischemic or cerebrovascular events [15–17].”
BackgroundBao, R.-H., Zhao, N., Jiang, X., Cong, Z.-H., Liu, J., Kang, L., Chen, Y.-H., Sun, J., Xing, W.-Y., Liu, J.-X., et al. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103277 · Cited by 6
Lin, Y., Wang, X., Lenz, L., Ndiaye, O. B., Qin, J., Wang, X., Huang, H., Jeuland, M., & Zhang, J. J. (2021) · Journal of Thoracic Disease · doi:10.21037/jtd-21-604 · Cited by 6
An overview of risk factors for stroke
Koltsova, E. A., Petrova, E. A., & Borshch, Y. V. (2022) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro202212212212 · Cited by 6
Putting genome analysis to good use: Lessons from C-reactive protein and cardiovascular disease
Manace, L. C., & Babyatsky, M. W. (2012) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.79a.09169 · Cited by 6
Fava, C., Montagnana, M., Guidi, G. C., & Melander, O. (2011) · Annals of Medicine · doi:10.3109/07853890.2011.582511 · Cited by 7
“As already stated, several studies have also evaluated the possibility that CRP plays a causal role in atherosclerosis progression, through the Mendelian randomization approach, but most of the interest has been focused on its predictive value as a biomarker (8).”
BackgroundChang, Y., Wu, W., & Hsu, L. (2011) · Molecular Biology Reports · doi:10.1007/s11033-011-1193-4 · Cited by 6
Anderson, T. J., Grégoire, J., Hegele, R. A., Couture, P., McPherson, R., Francis, G. A., Poirier, P., Lau, D. C. W., Grover, S. A., Carpentier, A. C., et al. (2013) · Cited by 9
Wada, N., Breen, E. C., Post, W. S., Stosor, V., Macatangay, B. J. C., & Margolick, J. B. (2021) · The Journals of Gerontology Series A · doi:10.1093/gerona/glab190 · Cited by 6
Maciocia, P. M. (2010) · Cardiovascular Therapeutics · doi:10.1111/j.1755-5922.2009.00128.x · Cited by 6
Ware, W. R. (2010) · Cited by 6
Burgess, S. (2012) · Apollo (University of Cambridge) · doi:10.17863/cam.16219 · Cited by 6
CRP Cutoff Value in East Asians With Coronary Heart Disease
Xiong, Y.-Y., Yu, M., Long, Q., Yang, F., Yuan, Y.-F., Xu, J., Liu, M., Nie, S., Yu, L., Libby, P., et al. (2026) · JACC Asia · doi:10.1016/j.jacasi.2026.01.005 · Cited by 7
Hara, T., & Sata, M. (2026) · Circulation Journal · doi:10.1253/circj.cj-26-0173 · Cited by 6
Development and Validation of a Risk Scoring Model for Early Prediction of Severe Colon Ischemia
Shin, M. Y., Moon, H. S., Kwon, I. S., Park, J. H., Kim, J., Kang, S. H., Lee, E. S., Kim, S. H., Sung, J. K., Lee, B. S., et al. (2020) · Digestive Diseases and Sciences · doi:10.1007/s10620-020-06717-1 · Cited by 5
Genomic Strategies Toward Identification of Novel Therapeutic Targets
Kessler, T., & Schunkert, H. (2020) · Handbook of experimental pharmacology · doi:10.1007/164_2020_360 · Cited by 8
Atere, A. D., Oseni, B. S., Adebua, I. P., Fapohunda, J., & Aigbokheo, I. F. (2018) · Sudan Journal of Medical Sciences · doi:10.18502/sjms.v13i4.3641 · Cited by 5
Ayari, F., Chaaben, A. B., Ammar, H. B., Nefzi, R., Ouni, N., Mihoub, O., Abaza, H., Aissa, A., Douik, H., Gara, S., et al. (2020) · L Encéphale · doi:10.1016/j.encep.2019.10.001 · Cited by 5
Prognostic role of serum high mobility group box 1 concentration in cardiac surgery
Kim, N., Lee, S., Lee, J. R., Kwak, Y. L., Jun, J.-H., & Shim, J. (2020) · Scientific Reports · doi:10.1038/s41598-020-63051-2 · Cited by 5
Zaczkiewicz, M., Kostenzer, K., Graf, M., Mayer, B., Zimmermann, O., & Torzewski, J. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11071762 · Cited by 5
HbA1c in Patients with Polycystic Ovary Syndrome: A Potential Marker of Inflammation.
Mortada, R. A., Kallail, K. J., Dong, F., & Karakas, S. E. (2015) · PubMed Central · Cited by 10
Endothelial Precursor Cells and CRP on the RAGE: Activation or Cell Death?
Yan, S. D., Bierhaus, A., Nawroth, P. P., & Stern, D. M. (2009) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e31819d6188 · Cited by 5
Genomic Medicine in the Prevention and Treatment of Atherosclerotic Cardiovascular Disease
Tuteja, S., & Rader, D. J. (2012) · Personalized Medicine · doi:10.2217/pme.12.34 · Cited by 5
Familial aggregation of circulating c-reactive protein in polycystic ovary syndrome
Sasidevi, A., Vellanki, P., Kunselman, A. R., Raja-Khan, N. T., Dunaif, A. E., & Legro, R. S. (2012) · Human Reproduction · doi:10.1093/humrep/des416 · Cited by 5
Williams, K. J., & Fisher, E. A. A. (2015) · Wiley eBooks · doi:10.1002/9781118828533.ch24 · Cited by 6
Genetics of Atherosclerotic Cardiovascular Disease
Qasim, A., & Reilly, M. P. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-383834-6.00061-6 · Cited by 4
Němečková, I., Eissazadeh, S., Rathouska, J., Šilhavý, J., Malínská, H., Pravenec, M., & Nachtigal, P. (2024) · BMC Cardiovascular Disorders · doi:10.1186/s12872-024-03870-7 · Cited by 5
AziziKia, H., Mousavi, A., Shojaei, S., Shaker, F., Salabat, D., Bahri, R. A., Dolama, R. H., & Radkhah, H. (2024) · Heart & Lung · doi:10.1016/j.hrtlng.2024.10.011 · Cited by 4
López, A., & Wright, J. M. (2012) · International Journal of Occupational and Environmental Health · doi:10.1179/1077352512z.0000000008 · Cited by 4
Ma, Y.-H., Zhao, L., Xian, X., Yang, D. D., Huang, W. Y., Wang, Y.-H., Mueller, O., Chang, E., Konigshofer, Y., Van-Cleve, M., et al. (2009) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2009.257 · Cited by 4
Libby, P. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-2930-6.00008-2 · Cited by 4
Epidemiologic Characterization of Risk for Cardiovascular Diseases
Maki, K. C., Dicklin, M. R., & Nieman, K. M. (2018) · Contemporary cardiology · doi:10.1007/978-3-319-97622-8_1 · Cited by 5
Boas, U., Daoud, M., Meier, S., Olsen, T. H., Gehring, K., Mogensen, D. J., & Heegaard, P. M. H. (2021) · Biomacromolecules · doi:10.1021/acs.biomac.1c00085 · Cited by 4
C- Reactive Protein in Tuberculosis and Human Immunodeficiency Virus Infections in Abeokuta, Nigeria
Ojo, D., Jacob, S., & Ayolabi, C. (2012) · Bayero Journal of Pure and Applied Sciences · doi:10.4314/bajopas.v4i2.18 · Cited by 4
Asferg, C. L., Andersen, U. B., Linneberg, A. R., Møller, D. V., Hedley, P. L., Christiansen, M., & Jeppesen, J. (2014) · American Journal of Hypertension · doi:10.1093/ajh/hpu029 · Cited by 4
Carrero, J. J., & Stenvinkel, P. (2010) · Springer eBooks · doi:10.1007/978-88-470-1463-3_7 · Cited by 4
“Indeed, although CRP haplotypes is associated with circulating CRP levels, an association to ischemic heart disease has not been observed [ 17 ].”
BackgroundChronic systemic inflammatory syndrome in patients with AECOPD presenting to emergency department.
Piras, O., Travaglino, F., Autunno, A., Bresciani, E., Corte, A. D., Lalle, I., & Somma, S. D. (2012) · PubMed · Cited by 4
Body fat distribution, inflammation and cardiovascular disease
Toss, F. (2011) · DiVA at Umeå University (Umeå University) · Cited by 5
Ørsted, D. D., Nordestgaard, B. G., & Bojesen, S. E. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.5_suppl.5 · Cited by 4
“Study participants were men examined in 1981–1983 in the Copenhagen CityHeart Study [12–15], thus, prior to the introduction of PSA testing into clinical practice in Denmark in 1995 [16].”
MethodSelf-citationGiannakopoulou, S., Chrysohoou, C. A., Antonopoulou, S., Barkas, F., Vlachogiannis, N., Kravvariti, E., Liberopoulos, E. N., Pitsavos, C., Tsioufis, C., Panagiotakos, D. B., et al. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.119212 · Cited by 4
Martín, A. S.-S., Méndez-Ocampo, P., Gutiérrez-Moctezuma, I., & Amezcua-Guerra, L. M. (2024) · Archivos de cardiología de México · doi:10.24875/acm.23000032 · Cited by 10
Suppression of cathepsin B attenuates myocardial injury via limiting cardiomyocyte apoptosis
Su, R., Sun, Z., Chen, T., Wu, H., Li, Z., Tang, Z., Zhao, J., & Xu, L. (2025) · Open Medicine · doi:10.1515/med-2024-1115 · Cited by 3
Taking Risk Prediction to the Next Level. Advances in Biomarker Research for Atherosclerosis
Siemelink, M. A., van der Laan, S. W., Timmers, L., Hoefer, I. E., & Pasterkamp, G. (2013) · Current Pharmaceutical Design · doi:10.2174/13816128113199990371 · Cited by 3
Serum C-reactive protein and carotid intima-media thickness
Kawada, T. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.01.050 · Cited by 3
Melichar, B., Kalábová, H., Krčmová, L. K., Kašparová, M., Plíšek, J., Hyšpler, R., Študentová, H., Zezulová, M., Holečková, P., Pecka, M., et al. (2010) · Pteridines · doi:10.1515/pteridines.2010.21.1.87 · Cited by 3
High CRP Levels After Critical Illness are Associated With an Increased Risk of Rehospitalization
Grander, W., Koller, B., Ludwig, C., Dünser, M. W., & Gradwohl-Matis, I. (2018) · Shock · doi:10.1097/shk.0000000000001118 · Cited by 3
Salica, A., Cammisotto, V., Scaffa, R., Folino, G., Paulis, R. D., Carnevale, R., Benedetto, U., Saade, W., Marullo, A. G. M., Sciarretta, S., et al. (2024) · Antioxidants · doi:10.3390/antiox13101180 · Cited by 3
MARCADORES CARDIACOS Y RIESGO CARDIOVASCULAR
David Doron, R., & Marcelo Muñoz, C. (2015) · Revista Médica Clínica Las Condes · doi:10.1016/j.rmclc.2015.04.002 · Cited by 9
Chronic Inflammatory Muscle Diseases and Risk of Coronary Artery Disease
Gundogdu, B. M., & Çilingiroğlu, M. (2013) · Current Atherosclerosis Reports · doi:10.1007/s11883-012-0308-2 · Cited by 3
Abd, M., Abbas, E. E., Mohamed, N. Y., & Mohie, W. (2013) · Cited by 3
Assessment of C-reactive protein titer in patients with chronic hepatitis B virus infection
Al-Ajeeli, K. S. (2011) · Iraqi Journal of Community Medicine · Cited by 3
CYP2C9 genotype does not affect risk of tobacco-related cancer in the general population
Kaur‐Knudsen, D., Nordestgaard, B. G., & Bojesen, S. E. (2010) · Cancer Epidemiology · doi:10.1016/j.canep.2010.01.003 · Cited by 3
Self-citationC-Reactive Protein and Cardiovascular Disease: Differences Between Humans and Mice
Jeppesen, J., & Asferg, C. L. (2010) · Hypertension · doi:10.1161/hypertensionaha.110.155077 · Cited by 3
Garofolo, L., Ferreira, S. R. G., & Miranda, F. (2014) · Revista do Colégio Brasileiro de Cirurgiões · doi:10.1590/s0100-69912014000300006 · Cited by 4
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Moneta, G. L. (2009) · Yearbook of Vascular Surgery · doi:10.1016/s0749-4041(08)79103-6 · Cited by 3
Devendra, G. P., & Krasuski, R. A. (2010) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32833e4f13 · Cited by 3
Rosuvastatin, C-reactive protein, LDL cholesterol, and the JUPITER trial
Bloom, J. M. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61232-0 · Cited by 3
C-reactive protein for risk assessment in coronary artery disease
Danchin, N. (2009) · Heart · doi:10.1136/hrt.2009.187179 · Cited by 3
Is Rheumatoid Arthritis a Causal Factor in Cardiovascular Disease?
Bridges, S. L., Niewold, T. B., & Merriman, T. R. (2022) · Arthritis & Rheumatology · doi:10.1002/art.42236 · Cited by 5
Bronze, L. (2022) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2021.11.009 · Cited by 3
Coronary Artery Disease and Myocardial Infarction
Damani, S. B., & Topol, E. J. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-382227-7.00046-x · Cited by 3
Kositsawat, J., Kuchel, G. A., Zhong, K., Zhao, S., Fortinsky, R. H., & Kuo, C.-L. (2025) · The Journals of Gerontology Series A · doi:10.1093/gerona/glaf272 · Cited by 2
Ridker, P. M. (2026) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2026.120687 · Cited by 2
Díaz, P. P., Huerta, J. A., Román, A. J., Pérez, I. S., Lluva, M. T. L., García, R. F., del Río, J. M., Alguacil, A. M., & Ruíz-Poveda, F. L. (2020) · Revista Colombiana de Cardiología · doi:10.1016/j.rccar.2019.11.007 · Cited by 4
Association of Serum C- Reactive Protein with Severity of Acute Ischemic Stroke Patients
Alam, M. N., Rahman, M., Showkat, T., Halder, P. C., Das, B., Halder, K. C., Ahmed, F., Akhtar, J., Akter, S., & Reza, M. M. (2021) · Scholars Journal of Applied Medical Sciences · doi:10.36347/sjams.2021.v09i12.016 · Cited by 2
High Ionized Calcium in the General Population and Risk of Primary Hyperparathyroidism
Kobylecki, C. J., Nordestgaard, B. G., & Afzal, S. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf106 · Cited by 2
Self-citationNordestgaard, A. G. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01393-4 · Cited by 3
Thomsen, M. J., Varbo, A., Tybjærg‐Hansen, A., & Nordestgaard, B. G. (2014) · Acta bioquímica clínica latinoamericana/Acta bioquímica clínica latinoamericana · Cited by 2
Self-citationInflammatory Cytokines and type 2 diabetes
Jokar, M. H., Sedighi, S., Aghaei, M., Mohamadkhani, A., & Moradzadeh, M. (2020) · کومش · doi:10.29252/koomesh.22.3.396 · Cited by 2
Munir, M., Bashir, H. B., & Qamar, M. (2021) · The Professional Medical Journal · doi:10.29309/tpmj/2021.28.03.5374 · Cited by 2
The year 2020 in Atherosclerosis
Binder, C. J., Borén, J., Catapano, A. L., Kronenberg, F., Mallat, Z., Negrini, S., Öörni, K., Raggi, P., & von Eckardstein, A. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.04.013 · Cited by 3
Chronische Inflammation und Biomarker: Ist Altern ein Ausdruck von chronischer Entzündung?
Schmidt, D., Kwetkat, A., & Gogol, M. (2011) · Zeitschrift für Gerontologie und Geriatrie · doi:10.1007/s00391-011-0198-x · Cited by 2
Olsen, M. H. (2010) · European Cardiology Review · doi:10.15420/ecr.2010.6.2.10 · Cited by 2
Recent Findings from Mendelian Randomization Studies of Cardiovascular Disease
Brown, I. J., & Elliott, P. (2010) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-010-0127-3 · Cited by 2
Nakou, E. S., Elisaf, M., & Liberopoulos, E. N. (2012) · The Open Clinical Chemistry Journal · doi:10.2174/1874241601003010010 · Cited by 2
Cardiovascular risk assessment
Blom, D. J. (2011) · South African Family Practice · doi:10.1080/20786204.2011.10874070 · Cited by 2
Genetically Elevated C-Reactive Protein and Ischemic Vascular Disease
Moneta, G. L. (2009) · Yearbook of Vascular Surgery · doi:10.1016/s0749-4041(08)79107-3 · Cited by 2
Novel Biomarkers and the Assessment of Cardiovascular Risk
Nambi, V., Brautbar, A., & Ballantyne, C. M. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-1366-4.00005-6 · Cited by 2
The Jupiter trial—new territory for statins?*
Wheeler, D. C. (2009) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfp237 · Cited by 2
“Polymorphisms in the CRP gene that are associated with higher plasma protein levels did not predict an increased risk of vascular disease, indicating that CRP is not in itself the causal factor [6].”
BackgroundYamasaki, T. (2013) · Angiology Open Access · doi:10.4172/2329-9495.1000108 · Cited by 2
Genetically Elevated C-Reactive Protein and Ischemic Vascular Disease
Gersh, B. J. (2009) · Yearbook of Cardiology · doi:10.1016/s0145-4145(09)79525-5 · Cited by 2
Sulaiman, D. M., Al-Shamma, K. J., & Al-Hassani, A. N. (2017) · Iraqi Journal of Pharmaceutical Sciences · doi:10.31351/vol22iss1pp5-17 · Cited by 2
Inflammation in Chronic Kidney Disease
Kovesdy, C. P., & Kalantar‐Zadeh, K. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4377-0987-2.00013-3 · Cited by 4
Acute Phase Reactants and the Concept of Inflammation
Nieves, C. E. F., Cronstein, B. N., & Saxena, A. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-31696-5.00057-7 · Cited by 3
Blankenberg, S., & Zeller, T. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-42880-4.00009-1 · Cited by 3
Genetics and Genomics of Atherosclerotic Cardiovascular Disease
Musunuru, K., Qasim, A., & Reilly, M. P. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-812532-8.00007-0 · Cited by 4
Use of High-Sensitivity C-Reactive Protein for Risk Assessment
Martin, S. S., Johnson, A. E., & Blumenthal, R. S. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-28786-9.00012-8 · Cited by 3
Chiabrando, J. G., Damonte, J. I., Piñel, S., Garmendia, C. M., de Chazal, H. M., Denicolai, M., Corna, G., Raleigh, J. V., Seropian, I. M., & Agatiello, C. R. (2024) · Minerva Cardiology and Angiology · doi:10.23736/s2724-5683.24.06477-9 · Cited by 2
Mohamed, R. A., Musa, M. M., & Ismail, A. M. (2015) · American Journal of Medicine and Medical Sciences · Cited by 2
Bang, O. Y. (2011) · Korean Journal of Stroke · doi:10.5853/kjs.2011.13.2.57 · Cited by 2
Lipoprotein(a) and cardiovascular disease: Make use of the knowledge we have
Kronenberg, F. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.11.016 · Cited by 2
Mattsson, N. (2012) · UTUPub (University of Turku) · Cited by 4
High-sensitivity C-reactive protein - a biomarker in stroke subtypes
Lauritzen, N. C. N., Larsson, L., Pedersen, U.-S. T., Henriksen, A. C., Nordestgaard, B. G., Sørensen, N. V., & Kruuse, C. R. (2025) · Neurological Research · doi:10.1080/01616412.2025.2571958 · Cited by 1
Self-citationBahrami, H. S. Z., Jørgensen, P. G., Hove, J. D., Dixen, U., Rasmussen, L. J. H., Eugen‐Olsen, J., Rossing, P. R., & Jensen, M. T. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-025-03071-2 · Cited by 1
Local to Systemic Inflammation—From Generation to Prognosis in Acute Coronary Syndrome
Melnic, M., Păduraru, L. F., Lorent, I.-A., Potcoava, A.-M., & Balanescu, S. M. (2026) · Biomedicines · doi:10.3390/biomedicines14040785 · Cited by 1
“Its association with the occurrence of cardiovascular events was investigated after its correlation with the atherosclerosis process, without demonstrating a causal relationship between elevated CRP values and atherosclerosis [35–38].”
Luo, J., Rasmussen, I. J., Thomassen, J. Q., & Frikke‐Schmidt, R. (2026) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2026.120824 · Cited by 1
Cardiovascular risk in inflamed Danish women and men without standard modifiable risk factors
Nordestgaard, A. T., Ridker, P. M., & Nordestgaard, B. G. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag349 · Cited by 1
Self-citation
Metadata
- Authors
- Zacho, J., Tybjærg-Hansen, A., Jensen, J. S., Grande, P., Sillesen, H., & Nordestgaard, B. G.
- Affiliations
- University of Copenhagen (DK)
- Herlev Hospital (DK)
- Rigshospitalet (DK)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-10-30
- Volume
- 359
- Issue
- 18
- Pages
- 1897-1908
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2081615427
- Cited by
- 839
- References
- 36
- Citations by year
- 2026: 22 · 2025: 21 · 2024: 21 · 2023: 21 · 2022: 26 · 2021: 25 · 2020: 33 · 2019: 25 · 2018: 28 · 2017: 40 · 2016: 48 · 2015: 44 · 2014: 61 · 2013: 56 · 2012: 76
- FWCI
- 102.24
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Life Sciences › Immunology and Microbiology › Immunology › Biomarkers in Disease Mechanisms
- Keywords
- C-reactive protein, ischemic heart disease, ischemic cerebrovascular disease, ischemic vascular disease, CRP gene polymorphisms, apolipoprotein E, high-sensitivity CRP, genetic association, cholesterol levels, causal relationship
- MeSH terms
- C-Reactive Protein, Cerebrovascular Disorders, Cross-Sectional Studies, Female, Humans, Male, Polymorphism, Genetic, Risk Factors, Cohort Studies, Biomarkers, Myocardial Ischemia, Genetic Predisposition to Disease, Atherosclerosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.